No Data
No Data
博安生物:2023年度報告
Boan Biotech (06955.HK) was granted a loan financing of 300 million yuan
Gelonghui, April 12, 丨 Boan Biotech (06955.HK) announced that on April 12, 2024, the company entered into a loan financing agreement with China Jingu International Trust Co., Ltd. (the “Lender”). Based on this, the lender agreed to provide the Company with a term loan of RMB 300 million. The board of directors believes that this financing will help advance the company's development strategy, enable the company to rapidly develop and market various products, and potentially accelerate the pace of successful commercialization. The financing is in line with the company's long-term goals and leverages the huge market potential of its product pipeline. The company is preparing to use this financing to effectively enhance its business operations, thereby investing in shares
Selected announcements | China's non-ferrous mining industry plans to sell up to 163 million shares at a discount of about 13.54%; Longyuan Electric Power's power generation will increase by about 10% during the year
China's net profit for the first quarter was 2,308 billion yuan, up 0.33% year on year; Qiutai Technology sold about 368.39 million mobile phone camera modules in March, up 31.8% from month to month, down 1.7% year on year.
Shandong Boan Biotechnology Completes Phase 3 Trial for Retina Injection
Shandong Boan Biotechnology (HKG:6955) completed its China phase 3 trial for its Aflibercept intravitreous injection indicated for retina and choroid pathological neovascular ophthalmopathy, accordin
Boan Biotech (06955.HK): Abbasip intraocular injection solution (BA9101) completed phase III clinical trials in China and plans to submit a marketing application
Boan Biotech (06955.HK) announced that the abacip intraocular injection solution (“BA9101”) developed by the company has completed phase III clinical trials (clinical efficacy and safety comparison test) in China and plans to submit a marketing application. Abacept is a homologous dimer glycoprotein formed by fusing the extracellular domain of human vascular endothelial growth factor receptor (VEGFR1Ig2 region and VEGFR2Ig3 region) with the Fc domain of human IgG1. It is a soluble inducer receptor that can bind to VEGF-A, VEGF-B, and PlGF, and can inhibit endogenous V
Shandong Boan Biotechnology Trims Attributable Loss in 2023
Shandong Boan Biotechnology (HKG:6955) said its loss attributable to owners narrowed to 119.4 million yuan in 2023 from 331.75 million yuan in 2022, according to a filing with the Hong Kong bourse on
No Data